[go: up one dir, main page]

PL3297628T3 - Azasetron do stosowania w leczeniu niedosłuchu - Google Patents

Azasetron do stosowania w leczeniu niedosłuchu

Info

Publication number
PL3297628T3
PL3297628T3 PL16725074T PL16725074T PL3297628T3 PL 3297628 T3 PL3297628 T3 PL 3297628T3 PL 16725074 T PL16725074 T PL 16725074T PL 16725074 T PL16725074 T PL 16725074T PL 3297628 T3 PL3297628 T3 PL 3297628T3
Authority
PL
Poland
Prior art keywords
azasetron
treatment
hearing loss
hearing
loss
Prior art date
Application number
PL16725074T
Other languages
English (en)
Inventor
Jonas DYHRFJELD-JOHNSEN
Original Assignee
Sensorion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sensorion filed Critical Sensorion
Publication of PL3297628T3 publication Critical patent/PL3297628T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL16725074T 2015-05-18 2016-05-18 Azasetron do stosowania w leczeniu niedosłuchu PL3297628T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562163177P 2015-05-18 2015-05-18
EP15167992 2015-05-18
PCT/EP2016/061119 WO2016184900A1 (en) 2015-05-18 2016-05-18 Calcineurin inhibitors of the setron family for the treatment of hearing loss
EP16725074.5A EP3297628B1 (en) 2015-05-18 2016-05-18 Azasetron for use in the treatment of hearing loss

Publications (1)

Publication Number Publication Date
PL3297628T3 true PL3297628T3 (pl) 2021-12-06

Family

ID=53199806

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16725074T PL3297628T3 (pl) 2015-05-18 2016-05-18 Azasetron do stosowania w leczeniu niedosłuchu

Country Status (13)

Country Link
US (2) US11433077B2 (pl)
EP (2) EP3909579A1 (pl)
JP (2) JP6994765B2 (pl)
CN (1) CN107847489B (pl)
CY (1) CY1124406T1 (pl)
ES (1) ES2882602T3 (pl)
HU (1) HUE056138T2 (pl)
PL (1) PL3297628T3 (pl)
PT (1) PT3297628T (pl)
RS (1) RS62226B1 (pl)
SI (1) SI3297628T1 (pl)
SM (1) SMT202100459T1 (pl)
WO (1) WO2016184900A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3297628T3 (pl) * 2015-05-18 2021-12-06 Sensorion Azasetron do stosowania w leczeniu niedosłuchu
PL3442537T3 (pl) * 2016-04-14 2024-07-15 Sensorion (+)-azasetron do zastosowania w leczeniu zaburzeń ucha
EA038516B1 (ru) * 2016-07-19 2021-09-09 Сенсорьон Композиция для лечения заболеваний уха, содержащая (+)-азасетрон
JP7044294B2 (ja) * 2017-09-21 2022-03-30 学校法人慶應義塾 音響外傷難聴モデル動物の作製用の音響暴露装置
CN112237009B (zh) 2018-01-05 2022-04-01 L·奥拉 助听器及其使用方法
US11095992B2 (en) * 2018-01-05 2021-08-17 Texas Institute Of Science, Inc. Hearing aid and method for use of same
CN108309964B (zh) * 2018-04-04 2020-06-30 军事科学院军事医学研究院环境医学与作业医学研究所 二甲双胍在制备噪声性听力损失防治产品中的应用
WO2021014014A1 (en) 2019-07-25 2021-01-28 Sensorion Treatment and/or prevention of lesions in the central auditory nervous system
EP4493194A1 (en) * 2022-03-16 2025-01-22 Sensorion Azasetron for the treatment of sudden sensorineural hearing loss
WO2025008371A1 (en) 2023-07-03 2025-01-09 Sensorion Azasetron for the preservation of residual hearing following cochlear implantation
US12108220B1 (en) 2024-03-12 2024-10-01 Laslo Olah System for aiding hearing and method for use of same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1304082C (en) * 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
RS20050851A (sr) * 2003-05-27 2008-04-04 Forest Laboratories Inc., Kombinacija antagonista nmda receptora i selektivnog inhibitora ponovnog preuzimanja serotonina za lečenje depresije i drugih poremećaja raspoloženja
CA2699213A1 (en) * 2007-09-12 2009-03-19 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of cochlear tinnitus
MX2011000545A (es) 2008-07-14 2011-02-24 Otonomy Inc Composiciones de liberacion controlada para la modulacion de apoptosis y metodos para el tratamiento de trastornos oticos.
DE102009003232A1 (de) * 2009-05-19 2010-12-02 Federal-Mogul Burscheid Gmbh Gleitelement eines Verbrennungsmotors, insbesondere Kolbenring
SMT201800184T1 (it) * 2009-05-20 2018-05-02 Inst Nat Sante Rech Med Antagonisti del recettore 5-ht3 della serotonina per uso nel trattamento di disordini da lesione vestibolare
EP2817009A1 (en) 2012-02-23 2014-12-31 INSERM - Institut National de la Santé et de la Recherche Médicale Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
ES2785303T3 (es) 2012-07-16 2020-10-06 Univ Cornell Nicotinamida ribósido para tratar la pérdida auditiva
PL3297628T3 (pl) * 2015-05-18 2021-12-06 Sensorion Azasetron do stosowania w leczeniu niedosłuchu
PL3442537T3 (pl) * 2016-04-14 2024-07-15 Sensorion (+)-azasetron do zastosowania w leczeniu zaburzeń ucha

Also Published As

Publication number Publication date
HUE056138T2 (hu) 2022-01-28
US11433077B2 (en) 2022-09-06
JP6994765B2 (ja) 2022-02-10
ES2882602T3 (es) 2021-12-02
RS62226B1 (sr) 2021-09-30
SI3297628T1 (sl) 2021-10-29
JP2018522938A (ja) 2018-08-16
PT3297628T (pt) 2021-08-16
SMT202100459T1 (it) 2021-09-14
JP2022028941A (ja) 2022-02-16
EP3297628A1 (en) 2018-03-28
US20220387438A1 (en) 2022-12-08
CN107847489A (zh) 2018-03-27
EP3909579A1 (en) 2021-11-17
EP3297628B1 (en) 2021-06-09
CN107847489B (zh) 2021-09-17
CY1124406T1 (el) 2022-07-22
WO2016184900A1 (en) 2016-11-24
US20180207167A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
IL269371A (en) Treatment methods
PL3297628T3 (pl) Azasetron do stosowania w leczeniu niedosłuchu
EP3160405A4 (en) Treatment of the ear
GB201608885D0 (en) Treatment
GB201502137D0 (en) Treatment
GB201522243D0 (en) Treatment
IL251904A0 (en) Epilimod for use in the treatment of melanoma
GB2543540B (en) Decellularising tissue
IL266701A (en) An implant with several cavities
IL270701A (en) Neurotrophins for use in the treatment of hearing loss
HK1247558A1 (zh) 塞內可瑞偉洛克(cenicriviroc)用於治療纖維化
GB201519450D0 (en) Novel treatment
GB201508841D0 (en) Treatment
IL262305B (en) Azasterone for use in the treatment of disorders related to the ear
EP3323368A4 (en) TREATMENT TOOL
GB201503008D0 (en) Treatment
LT3297628T (lt) Azasetronas, skirtas naudoti klausos praradimo gydymui
GB201718985D0 (en) Treatment
GB201713650D0 (en) Treatment
GB201706955D0 (en) Treatment
GB201617107D0 (en) Treatment
GB2555225B (en) Hydrocarbon-contamination treatment unit
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
GB201609683D0 (en) Treatment